This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cardinal Health (CAH) Q2 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Cardinal Health Inc. (CAH) reported second-quarter fiscal 2017 adjusted earnings of $1.34 per share, which beat the Zacks Consensus Estimate of $1.24 and increased 3% on a year-over-year basis.
Phirbo Animal (PAHC) Tops Q2 Earnings, Reaffirms FY17 View
by Zacks Equity Research
Phibro Animal Health Corporation (PAHC) reported adjusted earnings per share (EPS) of 39 cents in the second quarter of fiscal 2017.
QIAGEN (QGEN) Earnings Meet, Sales Miss Estimates in Q4
by Zacks Equity Research
QIAGEN N.V. (QGEN) reported fourth-quarter 2016 adjusted earnings per share (excluding restructuring expenses) of 39 cents, up 7.7% year over year.
IDEXX Laboratories (IDXX) Q4 Earnings Rise; Tweaks View
by Zacks Equity Research
IDEXX Laboratories Inc. (IDXX) recorded fourth-quarter 2016 earnings per share (EPS) of 58 cents, up 21% year over year on a reported basis.
Becton, Dickinson (BDX) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
Becton, Dickinson and Company (BDX) reported first-quarter fiscal 2017 earnings of $2.33 per share, which beat the Zacks Consensus Estimate by 22 cents and increased from $1.96 posted in the year-ago quarter.
Boston Scientific (BSX) Tops Q4 Earnings, Offers 2017 View
by Zacks Equity Research
Boston Scientific Corporation (BSX) posted adjusted earnings per share (EPS) of 30 cents, up 15.4% from the year-ago adjusted number.
Hologic (HOLX) Beats on Q1 Earnings, Lowers '17 Guidance
by Zacks Equity Research
Hologic Inc. (HOLX) reported first-quarter fiscal 2017 adjusted earnings per share (EPS) of 52 cents, up 13% year over year.
Edwards Lifesciences (EW) Beats on Earnings & Sales in Q4
by Zacks Equity Research
Edwards Lifesciences Corp. (EW) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%.
Accuray (ARAY) Incurs Wider Loss in Q2, Misses on Revenue
by Zacks Equity Research
Accuray Inc. (ARAY) reported a loss of 11 cents per share in the second quarter of fiscal 2017, wider than the Zacks Consensus Estimate of a loss of 7 cents.
Align Technology (ALGN) Q4 Earnings and Revenues in Line
by Zacks Equity Research
Align Technology Inc. (ALGN) reported adjusted earnings of 67 cents per share in the fourth quarter of 2016, up 11.6% from 60 cents in the year-ago quarter.
Illumina (ILMN) Beats Q4 Earnings & Revenues, Guides 2017
by Zacks Equity Research
Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 85 cents in the fourth quarter of 2016, which exceeded the Zacks Consensus Estimate by 4.9%.
Zimmer Biomet (ZBH) Beats on Q4 Earnings, Knees Improve
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) reported fourth-quarter 2016 adjusted earnings per share (EPS) of $2.14, up 2.4% year over year.
AmerisourceBergen (ABC) Q1 Earnings Beat, Revenues Lag
by Zacks Equity Research
AmerisourceBergen Corporation (ABC) posted earnings (excluding one-time items) of $1.36 per share in the first quarter of fiscal 2017, beating the Zacks Consensus Estimate of $1.24.
Hill-Rom TruSystem 3000 Table Boosts Surgical Solution Suite
by Zacks Equity Research
Hill-Rom Holdings (HRC) recently launched TruSystem 3000 Mobile Operating Table to fulfill hospitals' need to equip operating rooms with quality medical devices at a reasonable cost.
Thermo Fisher (TMO) Q4 Earnings Beat, Organic Sales Flat
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) reported better-than-expected fourth-quarter and full-year 2016 earnings results.
Hill-Rom (HRC) Q1 Earnings Meet, Revenues Lag Estimates
by Zacks Equity Research
Hill-Rom Holdings, Inc. (HRC) reported first-quarter fiscal 2017 adjusted earnings per share of 75 cents, up 10.3% from the year-ago quarter.
Abaxis (ABAX) Q3 Bleak: Earnings In Line, Revenues Miss
by Zacks Equity Research
Abaxis, Inc. (ABAX) - a global provider of point-of-care blood analyzers - reported third-quarter fiscal 2017 earnings per share of 30 cents, in line with the Zacks Consensus Estimate.
Cardiovascular Systems (CSII) Q2 Earnings Better Estimates
by Zacks Equity Research
Cardiovascular Systems, (CSII) reported earnings per share of 3 cents in second-quarter fiscal 2017, reflecting a massive improvement from the year-ago quarter's loss of 47 cents.
Mead Johnson (MJN) Misses Q4 Earnings, Sales; Guides '17
by Zacks Equity Research
Mead Johnson (MJN) reported fourth-quarter 2016 adjusted EPS of 78 cents, missing the Zacks Consensus Estimate of 83 cents by 6%.
Quest Diagnostics (DGX) Tops Q4 Earnings, Offers '17 View
by Zacks Equity Research
Quest Diagnostics' (DGX) fourth-quarter 2016 adjusted earnings per share (EPS) of $1.31 came in 4 cents ahead of the Zacks Consensus Estimate.
PetMed (PETS) Lags Q3 Earnings Estimates, Tops Revenues
by Zacks Equity Research
PetMed Express (PETS) announced earnings per share (EPS) of 24 cents for the third quarter of fiscal 2017.
Abbott Labs (ABT) Tops Q4 Earnings Estimates, Sales In Line
by Zacks Equity Research
Abbott Laboratories (ABT) reported fourth-quarter 2016 earnings from continuing operations of 65 cents per share, a penny higher than the Zacks Consensus Estimate.
ResMed (RMD) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
ResMed Inc. (RMD) announced second-quarter fiscal 2017 adjusted earnings per share (EPS) of 73 cents, consistent with the prior-year quarter level.
Quest Diagnostics (DGX) Launches HBV Quantitative Test
by Zacks Equity Research
Quest Diagnostics Inc. (DGX), a global provider of diagnostic information services, recently rolled out Hepatitis B Virus (HBV) Quantitative Test.
VWR Buys SEASTAR CHEMICALS to Boost Americas Division
by Zacks Equity Research
VWR Corporation (VWR) recently announced the acquisition of Canada-based SEASTAR CHEMICALS Inc.